How Similar Are Changes to the Surface of the Eye When Two Different Glaucoma Eye Drops Are Used?
Ocular Surface Changes With Topical Prostaglandin Analog Therapy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Wills Eye Glaucoma Service
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 21 or older
- Able to understand protocol and agree to 3 visits
- Any type of glaucoma
- Selective laser trabeculoplasty, Argon laser trabeculoplasty, peripheral iridotomy accepted
- Naïve: No prior glaucoma treatment (medical or surgical)
- If patient non-compliant, must be off meds 3 months
- Xalatan: At least one month use
Exclusion Criteria:
- Both Groups: Any history of ocular surface disease
- Dry eye syndrome or prior Restasis use
- Prior ocular surgery other than cataract extractions
- Uveitis or other inflammatory disease of the eye or adnexa
- Systemic medications that might influence ocular inflammation
- Any active inflammation or infection
- Pregnancy or intention to become pregnant
- Naïve: Prior use of topical glaucoma medication unless off for 3 months.
- Use of preserved artificial tear preparations in last 30 days and more than one year history of chronic use
- Xalatan: Prior use of Travatan or Travatan Z
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: New to Meds
Naive to glaucoma therapy medical or surgical.
All patients will receive Xalatan in the right eye and Travatan Z in the left eye.
|
one drop of Xalatan Ophthalmic Solution instilled in right eye at bedtime
Other Names:
one drop of Travatan Z Ophthalmic Solution instilled in left eye at bedtime
Other Names:
|
|
Other: Currently on Xalatan
Patients currently on Xalatan at least one month.
All patients will receive Xalatan in the right eye and Travatan Z in the left eye.
|
one drop of Xalatan Ophthalmic Solution instilled in right eye at bedtime
Other Names:
one drop of Travatan Z Ophthalmic Solution instilled in left eye at bedtime
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Tear Break up Time (TBUT)
Time Frame: Baseline, 1 month, 2 months
|
Difference of tear break up time (in seconds, average of 3 measurements) at one and two months after enrollment.
|
Baseline, 1 month, 2 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Tear Production
Time Frame: Baseline, 1 month, 2 months
|
Tear production, measured by Schirmer test in millimeters
|
Baseline, 1 month, 2 months
|
|
Conjunctival Hyperemia Score
Time Frame: Baseline, 1 month, 2 months
|
Conjunctival hyperemia is the amount of redness on the white part of the eye.
A total score was obtained by the sum of assessments in 6 areas of each eye are which are scored from 0 to 3 (0 = no redness; 3 = severe redness), then summed per eye for a total score range of 0-18 (0 = no redness; 18 = severe redness).
|
Baseline, 1 month, 2 months
|
|
Intraocular Pressure
Time Frame: Baseline, 1 month, 2 months
|
Intraocular pressure (the fluid pressure inside the eye) was measured two times in each eye using the Goldman applanation tonometer and averaged.
|
Baseline, 1 month, 2 months
|
|
Ocular Surface Disease Index Score
Time Frame: Baseline, 1 month, 2 months
|
Ocular Surface Disease Index Scores (OSDI) were obtained from a 12-item validated OSDI questionnaire completed by each participant.
This is an assessment related to eye comfort.
Each question's score ranges from 0 = no disability to 4 = greatest disability.
The total score is multiplied by 25 then divided by the number of questions answered then matched to a grid ranging from 0 to 100 with 0 having symptoms reported none of the time versus 100 having disability symptoms reported all of the time.
|
Baseline, 1 month, 2 months
|
|
Corneal Staining Score
Time Frame: Baseline, 1 month, 2 months
|
Corneal staining is an indication of the amount of dryness of the cornea (front clear part of the eye).
A total score was obtained by the sum of assessments in five areas of each eye which are scored from 0 to 3 (0 = no dryness; 3 = severe dryness), then summed per eye for a total score range of 0-15 (0 = no dryness; 15 = severe dryness).
|
Baseline, 1 month, 2 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Leslie J Katz, MD, Wills Eye Glaucoma Service
Publications and helpful links
General Publications
- Gupta SR, Ichhpujani P, Wizov SS, Wittpenn JR, Moster MR, Pro MJ, Rapuano CJ, Cruz-Colon C, Myers JS, Katz LJ. Effects of Latanoprost Versus Travoprost with Sofzia on Ocular Surface. ARVO E-abstract 168/A391 2010
- Rahmatnejad K, Rapuano CJ, Ichhpujani P, Wizov SS, Moster MR, Hark LA, Katz LJ. The Effects of Latanoprost With Benzalkonium Chloride Versus Travoprost With SofZia on the Ocular Surface. Eye Contact Lens. 2018 Nov;44 Suppl 2:S93-S98. doi: 10.1097/ICL.0000000000000405.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 08-875
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.